|
||||||||||||||||||||||||||||||||||||
| [
Contents
] [ INDEX ]
|
||||||||||||||||||||||||||||||||||||
| UDK 617.7:616.441-008.61 |
ISSN 035-2899, 39(2014) br.4 p.184-192 |
|||||||||||||||||||||||||||||||||||
|
Original paper Goiter size as a parameter for predicting remission in patients suffering from Graves disease treated by thyrosupressive drug therapy (Veličina strume kao parametar za predviđanje remisije kod pacijenata sa Grejvsovom bolešću lečenih medikamentnom tirosupresivnom terapijom) Aleksandar Aleksić (1), Željka Aleksić (2), Saška Manić (3), Vladimir Mitov (1), Aleksandar Jolić (1), Kosta Zdravković (4) (1) Odeljenje interne medicine, Zdravstveni centar Zaječar, (2) Služba nuklearne medicine, Zdravstveni centar Zaječar, (3) Odeljenje neurologije, Zdravstveni centar Zaječar, (4) Dnevna bolnica za hemioterapiju, Zdravstveni centar Vranje |
||||||||||||||||||||||||||||||||||||
|
|
||||||||||||||||||||||||||||||||||||
| Download in pdf format | Extended summary:
Graves' disease is defined as hyperthyroidism with diffuse goiter
caused by immune disorders. Efforts to identify factors that may
indicate the likelihood of achieving remission or relapse upon
cessation of thyrosupressive drug therapy are continuously ongoing.
Reports on the achievement of long-term remission range between
14-80% in the treated, and the overall rate of recurrence after
withdrawal of treatment is about 30-50%. Determination of the early
prognostic factors for the outcome of thyrosupressive drug therapy
could allow the differentiation between patients who respond and do
not respond to therapy and timely selection of ablative therapy. The
aim of this study was to determine the effect of goiter size as a
predictor of remission during thyrosupressive drug therapy. The
study was conducted in a prospective manner including 106
consecutive patients with newly diagnosed autoimmune
hyperethyroidism who were given thyrosupressive drug therapy. After
the diagnosis of the disease by anamnestic, clinical and biochemical
examination at the beginning and 12 months after the initiation of
thyrosupressive drug therapy, the presence and goiter size were
followed by palpation and by echosonographic volumetry. In the
majority of the patients (90%) at the beginning of the disease
goiter was small or absent (grade 0A, 0B, 0-I). During the MTT the
presence and goiter size did not change significantly. The average
thyroid volume at the beginning of the disease in our patients was
about 21 ml. During MTT and twelve months after the start of MTT,
significant changes in the size of thyroid were not observed. It was
observed that there was no significant difference in the presence
and goiter site, whether it was determined by palpation, or measured
echosonographically among patients in remission, and in those who
had no remission. The results indicate that the presence and goiter
size at the onset of the disease are not relevant for the prediction
of remission in patients with Graves' disease treated by the
thyrosupressive drug therapy. Keywords: goiter size, volume, remission, Graves' disease, hyperthyroidism Napomena: kompletan tekst rada na srpskom jeziku Note: full text in Serbian |
|||||||||||||||||||||||||||||||||||
|
|
||||||||||||||||||||||||||||||||||||
|
Corresponding Address: Aleksandar Aleksić Interno odeljenje, Zdravstveni Centar Zaječar, Rasadnička bb, 19 000 Zaječar, Srbija; E-mail: lukaal@ptt.rs |
Paper received: 18.8.2014 Paper accepted: 28.8.2014 Paper Internet issues: 17.11.2014 |
|||||||||||||||||||||||||||||||||||
| [
Contents
] [ INDEX ]
|
||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||
